Our latest white paper highlights our advanced plasma proteomics capabilities, driven by the P2 Enrichment System. The study demonstrates how TrueDiscovery® Plasma Biomarker Discovery services achieve an optimal balance between depth, throughput, and sensitivity, enabling their application in informed clinical decision-making.